Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability.
Prefrontal serotonin 5-HT(2) receptors have been linked to the pathogenesis and treatment of affective disorders, yet their function in psychiatric vulnerability is not known. Here, we examine the effects of 5-HT(2) receptors in a rat model of psychiatric vulnerability using electrophysiology, gene expression, and behavior. Following the early stress of chronic maternal separation, we found that serotonin has atypical 5-HT(2) receptor-mediated excitatory effects in the adult prefrontal cortex that were blocked by the 5-HT(2A) receptor antagonist MDL 100907. In the absence of a serotonergic agonist, the intrinsic excitability of the prefrontal cortex was not enhanced relative to controls. Yet, in response to stimulation of 5-HT(2) receptors, adult animals with a history of early stress exhibit heightened prefrontal network activity in vitro, enhanced immediate early gene expression in vivo, and potentiated head shake behavior. These changes arise in the absence of any major alteration of prefrontal 5-HT(2A/C) mRNA expression or 5-HT(2) receptor binding. Our microarray results and quantitative PCR validation provide insight into the molecular changes that accompany such enhanced 5-HT(2) receptor function in adult animals following early stress. We observed persistent prefrontal transcriptome changes, with significant enrichment of genes involved in cellular developmental processes, regulation of signal transduction, and G-protein signaling. Specific genes regulated by early stress were validated in an independent cohort, and several altered genes were normalized by chronic blockade of 5-HT(2) receptors in adulthood. Together, our results demonstrate enhanced prefrontal 5-HT(2) receptor function and persistent alterations in prefrontal gene expression in a rat model of psychiatric vulnerability.
Benekareddy
Madhurima
M
Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, India.
Goodfellow
Nathalie M
NM
Lambe
Evelyn K
EK
Vaidya
Vidita A
VA
D000386:AIDS-Related Complex / Q000235:genetics / Q000378:metabolism; D000662:Amphetamines / Q000633:toxicity; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D007650:Ketanserin / Q000493:pharmacokinetics; D008426:Maternal Deprivation; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D001523:Mental Disorders / Q000139:chemically induced / Q000473:pathology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques / Q000379:methods; D017397:Prefrontal Cortex / Q000166:cytology / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044348:Receptors, Serotonin, 5-HT2 / Q000235:genetics / Q000378:metabolism*; D012701:Serotonin / Q000494:pharmacology; D018490:Serotonin Agents / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D014316:Tritium / Q000493:pharmacokinetics
D000662:Amphetamines; D018691:Excitatory Amino Acid Antagonists; D012333:RNA, Messenger; D044348:Receptors, Serotonin, 5-HT2; D018490:Serotonin Agents; D012702:Serotonin Antagonists; D014316:Tritium; D012701:Serotonin; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine
Am J Psychiatry. 2002 Aug;159(8):1265-83
12153816
Eur J Pharmacol. 1999 Jul 28;378(1):23-30
10478561
Neurosci Lett. 1993 Nov 12;162(1-2):81-4
8121642
Ann N Y Acad Sci. 1999 Jun 29;877:383-96
10415660
J Clin Psychopharmacol. 2001 Feb;21(1):53-8
11199948
Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):515-9
7667378
J Neurophysiol. 2002 May;87(5):2490-504
11976386
J Neurophysiol. 1999 Dec;82(6):2989-99
10601434
J Neurosci. 2001 Dec 15;21(24):9856-66
11739593
Cereb Cortex. 2004 Mar;14(3):281-99
14754868
Neuropsychopharmacology. 2003 Feb;28(2):402-12
12589395
J Neurophysiol. 2004 Mar;91(3):1171-82
14602839
Neuropsychopharmacology. 2005 Dec;30(12):2192-204
15920504
J Neurosci. 2003 Apr 15;23(8):3373-84
12716945
J Neurosci. 2004 May 19;24(20):4807-17
15152041
Neuroscience. 2007 Mar 30;145(3):900-10
17293055
Curr Neuropharmacol. 2006 Apr;4(2):127-38
18615130
Neuroscience. 2009 Feb 18;158(4):1406-15
19111907
Arch Gen Psychiatry. 1999 Aug;56(8):705-11
10435604
Nat Protoc. 2009;4(1):44-57
19131956
Neuropsychopharmacology. 2008 Feb;33(3):574-87
17460614
J Neurosci. 2007 Feb 7;27(6):1467-73
17287521
Neuroreport. 1995 Apr 19;6(6):901-4
7612879
Prog Brain Res. 2000;126:413-31
11105660
Int J Neuropsychopharmacol. 2009 Jul;12(6):761-72
19102816
J Child Psychol Psychiatry. 2007 Mar-Apr;48(3-4):224-44
17355397
Cereb Cortex. 2004 Oct;14(10):1100-9
15115744
J Membr Biol. 1997 Mar 1;156(1):73-85
9070466
Science. 2006 Jul 28;313(5786):536-40
16873667
Brain Res. 1996 Jan 15;706(2):259-66
8822365
J Physiol. 2001 Apr 1;532(Pt 1):143-63
11283231
Neurosci Biobehav Rev. 2005;29(8):1335-46
16095695
J Psychiatry Neurosci. 2004 Jul;29(4):252-65
15309042
South Med J. 2008 Jun;101(6):612-7
18475223
Genome Biol. 2003;4(5):P3
12734009
Neuroscience. 2000;98(2):295-300
10854760
J Pharmacol Exp Ther. 1997 Aug;282(2):699-706
9262333
Am J Psychiatry. 2001 Jan;158(1):78-85
11136637
Brain Res. 1996 Nov 11;739(1-2):57-69
8955925
Hum Psychopharmacol. 2000 Aug;15(6):397-415
12404302
J Neurochem. 1996 Sep;67(3):1145-52
8752121
Neuron. 1994 Mar;12(3):529-40
7512349
Neuron. 2006 Feb 16;49(4):547-62
16476664
Brain Res Bull. 2001 Nov 15;56(5):441-51
11750789
Neuropsychopharmacology. 2007 Jul;32(7):1504-19
17164818
J Neurosci. 2001 Jul 1;21(13):4609-24
11425889
J Neurosci. 1997 Apr 15;17(8):2785-95
9092600
J Psychiatr Res. 2003 Sep-Oct;37(5):357-73
12849929
Psychopharmacology (Berl). 2007 Mar;190(4):497-506
17124620
Br J Pharmacol. 1990 Feb;99(2):221-2
1691671
J Clin Psychiatry. 2005 Oct;66(10):1321-5
16259547
Dev Psychopathol. 2001 Summer;13(3):419-49
11523842
Nucl Recept Signal. 2003;1:e012
16604184
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):55-60
12551726
Arch Gen Psychiatry. 2000 Sep;57(9):850-8
10986548
Neural Dev. 2009 May 18;4:17
19450252
Psychiatry Res. 1992 Dec;45(4):227-37
1292040
Metab Brain Dis. 2004 Jun;19(1-2):3-14
15214501
Neuroscience. 1997 Jan;76(2):441-8
9015328
Neurochem Int. 2006 Apr;48(5):350-7
16423427
Neuroscience. 2004;123(3):725-32
14706784
Nat Neurosci. 2010 May;13(5):622-9
20383137
Neuropharmacology. 2000 Jan 28;39(3):463-70
10698012
Biol Psychiatry. 1999 May 1;45(9):1085-98
10331101
Nat Neurosci. 2000 Oct;3(10):1027-34
11017176
J Neurosci. 2004 Jun 16;24(24):5603-10
15201333
Front Neurosci. 2010 Aug 13;4:
20802802
Neuropharmacology. 2007 Jun;52(8):1671-7
17493641
Brain Res Dev Brain Res. 1991 Jan 15;58(1):51-8
2015654
J Neurosci. 2003 Apr 1;23(7):2779-88
12684464
Synapse. 2001 Apr;40(1):1-10
11170216
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):416-8
19166896
Cereb Cortex. 2005 Jan;15(1):1-14
15238448
J Clin Psychopharmacol. 2008 Apr;28(2):156-65
18344725
Neuron. 2009 Jun 11;62(5):655-69
19524525